184 related articles for article (PubMed ID: 33411033)
21. YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma.
Dai H; Shao YW; Tong X; Wu X; Pang J; Feng A; Yang Z
Cancer Med; 2020 Mar; 9(5):1628-1637. PubMed ID: 31851786
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant chemoradiotherapy with cisplatin plus vinorelbine versus cisplatin plus fluorouracil for esophageal squamous cell carcinoma: A matched case-control study.
Liu SL; Yang H; Zhang P; Zhang L; Zhao L; Luo LL; Fu JH; Liu MZ; Xi M
Radiother Oncol; 2015 Aug; 116(2):262-8. PubMed ID: 26243678
[TBL] [Abstract][Full Text] [Related]
23. Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial.
Yang H; Liu H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Han Y; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Yang H; Li T; Lordick F; D'Journo XB; Cerfolio RJ; Korst RJ; Novoa NM; Swanson SJ; Brunelli A; Ismail M; Fernando HC; Zhang X; Li Q; Wang G; Chen B; Mao T; Kong M; Guo X; Lin T; Liu M; Fu J;
J Clin Oncol; 2018 Sep; 36(27):2796-2803. PubMed ID: 30089078
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903).
Sun HB; Xing WQ; Liu XB; Zheng Y; Yang SJ; Wang ZF; Liu SL; Ba YF; Zhang RX; Liu BX; Fan CC; Chen PN; Liang GH; Yu YK; Liu Q; Wang HR; Li HM; Li ZX;
BMC Cancer; 2020 Apr; 20(1):303. PubMed ID: 32293362
[TBL] [Abstract][Full Text] [Related]
25. Residual Cancer Volume Predicts Clinical Outcome in Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy.
Nakao R; Konishi E; Fujiwara H; Otsuji E; Yokota I; Urata Y; Yanagisawa A
Int J Surg Pathol; 2019 Oct; 27(7):713-721. PubMed ID: 31203677
[No Abstract] [Full Text] [Related]
26. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
[TBL] [Abstract][Full Text] [Related]
27. Polymorphisms of insulin-like growth factor binding protein-3 as a predictor for risk and patient survival in esophageal squamous cell carcinoma.
Zhao L; Chi F; Xi M; Shen JX; Li QQ; He LR; Liu SL; Liu MZ
Biomed Pharmacother; 2015 Aug; 74():148-52. PubMed ID: 26349977
[TBL] [Abstract][Full Text] [Related]
28. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
29. SUV
Nagaki Y; Motoyama S; Sato Y; Wakita A; Fujita H; Sasaki Y; Imai K; Minamiya Y
World J Surg Oncol; 2021 Apr; 19(1):105. PubMed ID: 33836789
[TBL] [Abstract][Full Text] [Related]
30. Survival Impact of Total Resected Lymph Nodes in Esophageal Cancer Patients With and Without Neoadjuvant Chemoradiation.
Ho HJ; Chen HS; Hung WH; Hsu PK; Wu SC; Chen HC; Wang BY
Ann Surg Oncol; 2018 Dec; 25(13):3820-3832. PubMed ID: 30284131
[TBL] [Abstract][Full Text] [Related]
31. Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma.
Ochi M; Murakami Y; Nishibuchi I; Kubo K; Imano N; Takeuchi Y; Kimura T; Hamai Y; Emi M; Okada M; Nagata Y
J Radiat Res; 2021 Jan; 62(1):142-148. PubMed ID: 33392619
[TBL] [Abstract][Full Text] [Related]
32. EGFR Expression in Patients with Esophageal Squamous Cell Carcinoma and its Association with Pathologic Response to Preoperative Chemoradiotherapy: A Study in Northeastern Iran.
Anvari K; Sima HR; Seilanian Toussi M; Anvari A; Shahidsales S; Memar B; Aledavoud SA; Forghani MN; Abdollahi A; Ghaffarzadegan K
Arch Iran Med; 2017 Apr; 20(4):240-245. PubMed ID: 28412829
[TBL] [Abstract][Full Text] [Related]
33. TIM-3 polymorphism is involved in the progression of esophageal squamous cell carcinoma by regulating gene expression.
Cui SJ; Li Y; Zhou RM; Liu L; Cao SR; Huang X; Huo XR; Wang N
Environ Mol Mutagen; 2021 Apr; 62(4):273-283. PubMed ID: 33723872
[TBL] [Abstract][Full Text] [Related]
34. Utility of weekly docetaxel combined with preoperative radiotherapy for locally advanced esophageal cancer from pathological analysis.
Kushida T; Nohara S; Yoshino K; Fujiwara D; Ouchi K; Amano T; Isayama F; Tomita N; Iwanuma Y; Sasai K; Tsurumaru M; Kajiyama Y
Dis Esophagus; 2014; 27(4):368-73. PubMed ID: 23865505
[TBL] [Abstract][Full Text] [Related]
35. Tumor Remission and Tumor-Infiltrating Lymphocytes During Chemoradiation Therapy: Predictive and Prognostic Markers in Locally Advanced Esophageal Squamous Cell Carcinoma.
Qian D; Wang Y; Zhao G; Cao F; Er P; Chen X; Cheng J; Zhang W; Li X; Zhang B; Guan Y; Zhou D; Wang J; Jiang H; Yu Z; Yuan Z; Wang P; Pang Q
Int J Radiat Oncol Biol Phys; 2019 Oct; 105(2):319-328. PubMed ID: 31228553
[TBL] [Abstract][Full Text] [Related]
36. Radical esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma followed by adjuvant radiotherapy with or without chemotherapy: Which is more beneficial?
Zou B; Tu Y; Liao D; Xu Y; Wang J; Huang M; Ren L; Zhu J; Gong Y; Liu Y; Zhou L; Zhou X; Peng F; Lu Y
Thorac Cancer; 2020 Mar; 11(3):631-639. PubMed ID: 31943824
[TBL] [Abstract][Full Text] [Related]
37. [The value of the planned neoadjuvant radiotherapy or chemoradiotherapy for the non-radical resection of esophageal squamous cell carcinoma].
Ni WJ; Deng W; Xiao ZF; Zhou ZM; Wang X; Chen DF; Feng QF; Liang J; Lyu JM; Bi N; Deng L; Zhang T; Wang WQ; Xue Q; Gao SG; Mu JW; Mao YS; Wang DL; Zhao J; Gao YS; Huang JF; Tan FW; Zhao L; Lyu F; Zhang GC
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):295-302. PubMed ID: 31014056
[No Abstract] [Full Text] [Related]
38. Adjuvant chemotherapy does not benefit patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.
Chen M; Shen M; Lin Y; Liu P; Liu X; Li X; Li A; Yang R; Ni W; Zhou X; Zhang L; Xu B; Lin J; Chen J; Tian Y
Radiat Oncol; 2018 Aug; 13(1):150. PubMed ID: 30111361
[TBL] [Abstract][Full Text] [Related]
39. Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
Chiu CH; Chen WH; Wen YW; Yeh CJ; Chao YK; Chang HK; Tseng CK; Liu YH
Dis Esophagus; 2016 Aug; 29(6):634-41. PubMed ID: 26175202
[TBL] [Abstract][Full Text] [Related]
40. Risk factors for esophageal fistula in thoracic esophageal squamous cell carcinoma invading adjacent organs treated with definitive chemoradiotherapy: a monocentric case-control study.
Kawakami T; Tsushima T; Omae K; Ogawa H; Shirasu H; Kito Y; Yoshida Y; Hamauchi S; Todaka A; Machida N; Yokota T; Yamazaki K; Fukutomi A; Onozawa Y; Yasui H
BMC Cancer; 2018 May; 18(1):573. PubMed ID: 29776344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
